TAK-593

• CAT Number: I000092
• CAS Number: 1005780-62-0
• Molecular Formula: C23H23N7O3
• Molecular Weight: 445.47
• Purity: ≥95%
• Target: PDGFR
• Solubility: DMSO: ≥ 48.5 mg/mL
• Storage: Store at -20°C
• IC50: 3.2/0.95/1.1 nM(VEGFR1/2/3); 4.3/1/13 nM(PDGFRα/PDGFRα V561D/PDGFRβ) [1]
• IUPAC Name: N-[5-[2-(cyclopropanecarbonylamino)imidazo[1,2-b]pyridazin-6-yl]oxy-2-methylphenyl]-2,5-dimethylpyrazole-3-carboxamide
• InChI: InChI=1S/C23H23N7O3/c1-13-4-7-16(11-17(13)24-23(32)18-10-14(2)27-29(18)3)33-21-9-8-20-25-19(12-30(20)28-21)26-22(31)15-5-6-15/h4,7-12,15H,5-6H2,1-3H3,(H,24,32)(H,26,31)
• InChIKey: DZFZXPPHBWCXPQ-UHFFFAOYSA-N
• SMILES: CC1=C(C=C(C=C1)OC2=NN3C=C(N=C3C=C2)NC(=O)C4CC4)NC(=O)C5=CC(=NN5C)C

TAK-593(CAT: I000092) is a potent and selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), widely utilized in oncology research. By targeting VEGFR2, it effectively disrupts angiogenesis, the process of new blood vessel formation, which is crucial for tumor growth and metastasis. TAK-593 is particularly valuable in studying cancer types that rely on VEGF-driven signaling pathways. With high specificity and efficacy, it is suitable for in vitro and in vivo studies, supporting the development of targeted therapies that inhibit angiogenesis in cancer and other VEGFR2-associated diseases.